Teva to Present at the Jefferies London Healthcare Conference
Teva Pharmaceutical Industries (NYSE and TASE: TEVA) announced that their President and CEO, Richard Francis, will deliver a presentation at the Jefferies London Healthcare Conference on November 19, 2024, at 8:30 AM GMT (3:30 AM ET). The presentation will be accessible via live webcast on Teva's Investor Relations website, with an archived version available within 24 hours after the live session concludes.
Teva Pharmaceutical Industries (NYSE e TASE: TEVA) ha annunciato che il loro Presidente e CEO, Richard Francis, terrà una presentazione alla Jefferies London Healthcare Conference il 19 novembre 2024, alle 8:30 AM GMT (3:30 AM ET). La presentazione sarà accessibile tramite webcast dal vivo sul sito delle Relazioni con gli Investitori di Teva, con una versione registrata disponibile entro 24 ore dalla conclusione della sessione dal vivo.
Teva Pharmaceutical Industries (NYSE y TASE: TEVA) anunció que su Presidente y CEO, Richard Francis, realizará una presentación en la Jefferies London Healthcare Conference el 19 de noviembre de 2024, a las 8:30 AM GMT (3:30 AM ET). La presentación será accesible a través de un webcast en vivo en el sitio web de Relaciones con Inversores de Teva, con una versión archivada disponible dentro de las 24 horas siguientes a la conclusión de la sesión en vivo.
테바 제약 산업 (NYSE 및 TASE: TEVA)은 그들의 회장兼 CEO인 리차드 프랜시스가 2024년 11월 19일 오전 8시 30분 GMT (오전 3시 30분 ET)에 제퍼리스 런던 헬스케어 콘퍼런스에서 발표를 할 것이라고 발표했습니다. 발표는 테바의 투자자 관계 웹사이트에서 라이브 웹캐스트를 통해 접근할 수 있으며, 라이브 세션 종료 후 24시간 이내에 기록된 버전을 이용할 수 있습니다.
Teva Pharmaceutical Industries (NYSE et TASE : TEVA) a annoncé que son Président et CEO, Richard Francis, présentera une conférence à la Jefferies London Healthcare Conference le 19 novembre 2024, à 8h30 GMT (3h30 ET). La présentation sera accessible via un webcast en direct sur le site Relations Investisseurs de Teva, avec une version archivée disponible dans les 24 heures suivant la fin de la session en direct.
Teva Pharmaceutical Industries (NYSE und TASE: TEVA) gab bekannt, dass ihr Präsident und CEO, Richard Francis, am 19. November 2024 um 8:30 Uhr GMT (3:30 Uhr ET) bei der Jefferies London Healthcare Conference eine Präsentation halten wird. Die Präsentation wird über einen Live-Webcast auf der Investor-Relations-Website von Teva zugänglich sein, mit einer archivierten Version, die innerhalb von 24 Stunden nach Abschluss der Live-Sitzung verfügbar sein wird.
- None.
- None.
TEL AVIV, Israel, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024. The presentation will begin at 8:30 A.M. Greenwich Mean Time (3.30 A.M. Eastern Time).
To access a live webcast of the presentation, visit Teva’s Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations.
An archived version of the webcast will be available within 24 hours after the end of the live discussion.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader, harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern medicine. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its ~37,000 employees across 58 markets to push the boundaries of scientific innovation and deliver quality medicines to help improve health outcomes of millions of patients every day. To learn more about how Teva is all in for better health, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This document and the presentation at the conference may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace including our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generics medicines; our substantial indebtedness; our business and operations in general including the impact of global economic conditions and other macroeconomic developments and the governmental and societal responses thereto; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the third quarter of 2024 and in our Annual Report on Form 10-K for the year ended December 31, 2023, including in the sections captioned "Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
IR Contacts | Ran Meir | +1 (215) 591-8912 | |
Yael Ashman | +972 (3) 914 8262 | ||
Sanjeev Sharma | +1 (973) 658 2700 | ||
PR Contacts | Kelley Dougherty Eden Klein | +1 (973) 832-2810 +972 (3) 906 2645 |
FAQ
When is Teva (TEVA) presenting at the Jefferies London Healthcare Conference 2024?
How can I watch Teva's (TEVA) presentation at the Jefferies London Healthcare Conference?
Will Teva's (TEVA) Jefferies Conference presentation be available for replay?